References
- Vengelen-Tyler V, ed. Technical manual. 13th ed. Bethesda, MD: American Association of Blood Banks, 1999.
- Saba NF, Sweeney JD, Lawton JC, Yankee RL, Huang CH, Schanfield MS. Anti-D in a D-positive renal transplant patient. Transfusion 1997;37:321-4.
- Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oxford: Blackwell Science, 1997.
- Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-7.
- Bergman L. Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia 1997;11(Suppl 2):S29-S34.
- Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström’s macroglobulinemia: clinical features, complications and management. J Clin Oncol 2000;18:214-26.
- Tetreault SA, Saven A. Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenström’s macroglobulinemia. Leukemia and Lymphoma 2000;37:125-30.
- Gassner C, Schmarda A, Kilga-Nogler S, et. al. Rhesus D/CE typing by polymerase chain reaction using sequence-specific primers. Transfusion 1997; 37:1020-26.
- Callaghan TA, Fleetwood P, Contreras M, Scherrmann JM. Human monoclonal anti-D with a normal halflife. Transfusion 1993;33:784-5.
- Petz LD, Garratty G. Mechanisms of immune hemolysis. In: Petz LD, Garratty G, eds. Acquired immune hemolytic anemias. London: Churchill Livingston, 1980:110-38.
- Issitt PD. Serology and genetics of the Rhesus blood group system. Cincinnati, OH: Montgomery Scientific Publications 1979:161-7.
- Avent ND, Reid ME. The Rh blood group system: a review. Blood 2000;95:375-87.
- Vagace JM, Bureo JC, Groiss J, et al. Autoanticuerpos con especificidad anti-D. Comunicación de dos casos y revisión del tema. Haematologica 2000;85:375-87.
- Myint H, Copplestone JA, Orchand J, et. al. Fludarabine-related autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia. Br J Haematol 1995;91:341-4.
- Juliusson G. Complications in the treatment of CLL with purine analogues. Haematology Cell Ther 1997;39:S41-S44.
- DiRaimondo F, Giustolisi R, Cacciola E, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leukemia Lymphoma 1993;11:63-8.
- Robak T, Blasinska-Morawiec M, Kryowski E, Hellman A, Konopa L. Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 1997;58:109-13.
- Cheson BD. Infections and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995;13:28-33.
- Kong LR, Huang C, Hakimian D, et al. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin’s lymphoma. Cancer 1998;82:957-64.
- Fleischman A, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia (letter). Am J Haematol 1995;48:293.
- Piro LD, Carrera CJ, Beutler E, Carson DA. 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069-73.
- Weiss RB, Freeman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998;16:1885-9.
- Byrd JC, Hertler AA, Weiss RB, Freimann J, Kweder SL, Dieth LF. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy with a history of fludarabine-associated hemolytic anemia. Ann Oncol 1995;6:300-1.